R
Robyn J. Levy
Publications - 32
Citations - 2607
Robyn J. Levy is an academic researcher. The author has contributed to research in topics: Hereditary angioedema & Angioedema. The author has an hindex of 19, co-authored 32 publications receiving 2372 citations.
Papers
More filters
Journal ArticleDOI
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema
Marco Cicardi,Aleena Banerji,F. Bracho,Alejandro Malbrán,Bernd Rosenkranz,Marc A. Riedl,Konrad Bork,William R. Lumry,Werner Aberer,Henning Bier,Murat Bas,Jens Greve,Thomas K. Hoffmann,Henriette Farkas,Avner Reshef,Bruce Ritchie,William H. Yang,Jürgen Grabbe,Shmuel Kivity,Wolfhart Kreuz,Robyn J. Levy,Thomas A. Luger,Krystyna Obtułowicz,Peter Schmid-Grendelmeier,Christian Bull,Brigita Sitkauskiene,William B Smith,Elias Toubi,Sonja Werner,Suresh Anné,Janne Björkander,Laurence Bouillet,Enrico Cillari,D. Hurewitz,Kraig W. Jacobson,Constance H. Katelaris,Marcus Maurer,Hans F. Merk,Jonathan A. Bernstein,Conleth Feighery,Bernard Floccard,Gerald J. Gleich,Jacques Hébert,Martin Kaatz,Paul K. Keith,Charles H. Kirkpatrick,David Langton,Ludovic Martin,Christiane Pichler,David Resnick,Duane Wombolt,Diego S. Fernández Romero,Andrea Zanichelli,Francesco Arcoleo,Jochen Knolle,Irina Kravec,Liying Dong,Jens Zimmermann,Kimberly Rosen,Wing Tze Fan +59 more
TL;DR: In patients with hereditary angioedema having acute attacks, a significant benefit of icatibant as compared with tranexamic acid in one trial and a nonsignificantbenefit of ic atibant in the other trial are found with regard to the primary end point.
Journal ArticleDOI
Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema
Bruce L. Zuraw,Bruce L. Zuraw,Paula J. Busse,Martha V. White,Joshua J. Jacobs,William R. Lumry,James R. Baker,Timothy J. Craig,J. Andrew Grant,D. Hurewitz,Leonard Bielory,William E. Cartwright,Majed Koleilat,Walter Ryan,Oren P. Schaefer,Michael E. Manning,Pragnesh Patel,Jonathan A. Bernstein,Roger A. Friedman,Robert J. Wilkinson,David C. Tanner,Gary Kohler,Glenne Gunther,Robyn J. Levy,James T. McClellan,Joseph Redhead,David A. Guss,Eugene Heyman,Brent A. Blumenstein,Ira Kalfus,Michael M. Frank +30 more
TL;DR: In subjects with hereditary angioedema, nanofiltered C1 inhibitor concentrate shortened the duration of acute attacks and when used for prophylaxis reduced the frequency of acute Attacks.
Journal ArticleDOI
Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks
Timothy J. Craig,Robyn J. Levy,Richard L. Wasserman,Againdra K. Bewtra,D. Hurewitz,Krystyna Obtułowicz,Avner Reshef,Bruce Ritchie,Dumitru Moldovan,Todor Shirov,Vesna Grivcheva-Panovska,Peter Kiessling,Heinz Otto Keinecke,Jonathan A. Bernstein +13 more
TL;DR: C1 esterase inhibitor concentrate given intravenously at a dose of 20 U/kg is an effective and safe treatment for acute abdominal and facial attacks in patients with hereditary angioedema, with a rapid onset of relief.
Journal ArticleDOI
Ecallantide for the treatment of acute attacks in hereditary angioedema.
Marco Cicardi,Robyn J. Levy,Donald L. McNeil,H. Henry Li,Albert L. Sheffer,Marilyn Campion,Patrick T. Horn,William E. Pullman +7 more
TL;DR: Four hours after administration of ecallantide or placebo for acute attacks of angioedema in patients with hereditary angioEDema, patient-reported treatment outcome scores and mean symptom complex severity scores were significantly better with ecallanide than with placebo.
Journal ArticleDOI
Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema
Bruce L. Zuraw,Marco Cicardi,Robyn J. Levy,Jan H. Nuijens,Anurag Relan,Sonja Visscher,Gerald Haase,Leonard Kaufman,C. Erik Hack +8 more
TL;DR: Administration of rhC1INH at 100 or 50 U/kg was highly effective as a treatment of acute attacks in patients with HAE and appeared to be safe and well tolerated.